Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment

Karlijn Verkerk; Hans-Martin Otten; Alwin D R Huitema

doi:10.1007/s00280-022-04476-6

Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment

Karlijn Verkerk, Hans-Martin Otten, Alwin D R Huitema

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.

Original language	English
Pages (from-to)	417-419
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	90
Issue number	5
DOIs	https://doi.org/10.1007/s00280-022-04476-6
Publication status	Published - Nov 2022

Keywords

Antineoplastic Agents/therapeutic use
Asparaginase/therapeutic use
Brain Diseases/chemically induced
Cisplatin
Cisplatin/adverse effects
Cytarabine/adverse effects
Deoxycytidine/analogs & derivatives
Fluorouracil
Gemcitabine
Humans
Hyperammonemia
Hyperammonemia/chemically induced
Hyperammonemic encephalopathy
Neurotoxicity Syndromes/drug therapy

Access to Document

10.1007/s00280-022-04476-6

Cite this

@article{a109340c7da641d790b569435f5418b1,

title = "Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment",

abstract = "Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.",

keywords = "Antineoplastic Agents/therapeutic use, Asparaginase/therapeutic use, Brain Diseases/chemically induced, Cisplatin, Cisplatin/adverse effects, Cytarabine/adverse effects, Deoxycytidine/analogs & derivatives, Fluorouracil, Gemcitabine, Humans, Hyperammonemia, Hyperammonemia/chemically induced, Hyperammonemic encephalopathy, Neurotoxicity Syndromes/drug therapy",

author = "Karlijn Verkerk and Hans-Martin Otten and Huitema, {Alwin D R}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2022",

month = nov,

doi = "10.1007/s00280-022-04476-6",

language = "English",

volume = "90",

pages = "417--419",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer-Verlag",

number = "5",

}

TY - JOUR

T1 - Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment

AU - Verkerk, Karlijn

AU - Otten, Hans-Martin

AU - Huitema, Alwin D R

PY - 2022/11

Y1 - 2022/11

N2 - Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.

AB - Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.

KW - Antineoplastic Agents/therapeutic use

KW - Asparaginase/therapeutic use

KW - Brain Diseases/chemically induced

KW - Cisplatin

KW - Cisplatin/adverse effects

KW - Cytarabine/adverse effects

KW - Deoxycytidine/analogs & derivatives

KW - Fluorouracil

KW - Gemcitabine

KW - Humans

KW - Hyperammonemia

KW - Hyperammonemia/chemically induced

KW - Hyperammonemic encephalopathy

KW - Neurotoxicity Syndromes/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85138395131&partnerID=8YFLogxK

U2 - 10.1007/s00280-022-04476-6

DO - 10.1007/s00280-022-04476-6

M3 - Article

C2 - 36127544

SN - 0344-5704

VL - 90

SP - 417

EP - 419

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this